Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5413760 | 0.91 | HRH3 (0.54) | HRH3KDM4ERAB9ANPC1PKM | |
| SCHEMBL5261256 | 0.86 | NPC1 (0.54) | HRH3KDM4ERAB9ANPC1PKM | |
| SCHEMBL5427076 | 0.80 | HRH3 (0.64) | HRH3KDM4ERAB9ANPC1PKM | |
| SCHEMBL5413880 | 0.80 | HRH3 (0.69) | HRH3KDM4ERAB9ANPC1PKM | |
| SCHEMBL6295832 | 0.72 | HRH3 (1.00) | HRH3TLR9TLR7 | |
| SCHEMBL5260036 | 0.72 | HRH3 (1.00) | HRH3TLR9TLR7 | |
| SCHEMBL5263773 | 0.71 | HRH3 (0.73) | HRH3KDM4ERAB9ANPC1PKM | |
| SCHEMBL5261351 | 0.70 | HRH3 (0.63) | HRH3KDM4ERAB9ANPC1PKM | |
| SCHEMBL5413761 | 0.70 | HRH3 (0.68) | HRH3KDM4ERAB9ANPC1PKM | |
| SCHEMBL14528958 | 0.68 | SMN1; SMN2 (0.54) | HRH3KDM4ERAB9ANPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199117-B2 | Phenyl-substituted imidazopyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7087757-B2 | Phenyl-substituted imidazopyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20050085502-A1 | Phenyl-substituted imidazopyridines | BREITENBUCHER J G (US) | 2005-04-21 | — | — | US | disclosed |
| US-20050043348-A1 | Phenyl-substituted imidazopyridines | BREITENBUCHER J GUY (US) | 2005-02-24 | — | — | US | disclosed |
| EP-1268478-A2 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES | Ortho McNeil Pharmaceutical, Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020006934-A1 | Phenyl-substituted imidazopyridines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001074815-A2 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043348-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | HRH3 701/4885KDM4E 1467/4885RAB9A 3610/4885 |
| US-20050085502-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | HRH3 701/4885KDM4E 1467/4885RAB9A 3610/4885 |
| US-20020006934-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | HRH3 701/4885KDM4E 1467/4885RAB9A 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.